The objective of the Summit is to identify priority research topics that should be addressed at European level. In doing so, we will hear over the coming days from all stakeholders – medical professionals, patients, pharmaceutical industry, research funders and research policymakers. This approach builds on the work of previous Presidential Summits – which saw the European Respiratory Roadmap and a focus on health inequalities providing the background from which to tackle respiratory disease. The outcomes will be valuable to our Society in the coming months – as a basis for focusing our potential scientific and research activities and indeed as a basis for advocacy and discussion with the European Commission.
Opening & welcome F. Blasi (Milan, Italy)
| |
Keynote address E. Meehan (Dublin, Ireland)
| |
WHO actions to promote lung health H. Kluge (Copenhagen, Denmark)
| |
Strategic research priority setting for health in Horizon 2020 H. Laverty (Brussels, Belgium)
| |
Health Research collaboration in Europe: an innovative initiative G. Kogan (Brussels, Belgium)
| |
Health priorities during the Lithuanian Presidency A. Veryga (Ministry of Health, Lithuania)
| |
Discussion
| |
Tobacco and the global attack on lung health W. MacNee (Edinburgh, United Kingdom)
| |
From home to the work place: the impact of air quality N. Kuenzli (Basel, Switzerland)
| |
The rising epidemic of social inequalities in Europe I. Annesi-Maesano (Paris, France)
| |
Discussion
| |
Meeting the challenge of AMR and respiratory infections F. Blasi (Milan, Italy), Tobias Welte (Hanover, Germany)
| |
Personalised medicine: a step forward to better care? S. Holgate (Southampton, United Kingdom)
| |
Comorbidities and the ageing lung J. Vestbo (Odense, Denmark)
| |
Mainstreaming research for rare diseases J-P. Sculier (Brussels, Belgium)
| |
Panel discussion: identify concrete areas/topics where collaboration at EU-level is necessary. P.J. Barnes (London, United Kingdom), S. Holgate (Southampton, United Kingdom), K.F. Rabe (Großhansdorf, Germany), T. Welte (Hanover, Germany), J-P. Sculier (Brussels, Belgium), J. Vestbo (Odense, Denmark), B. Flood (Wexford, Ireland)
| |
Key role of patients in clinical trials R. Mccrory (Co Down, Ireland)
| |
Challenge of adherence to treatment in chronic diseases G. Canonica (Genoa, Italy)
| |
Living with a rare disease: LAM patient’s view E. Reilly (Dublin, Ireland)
| |
Living with a rare disease: CF patient’s view K. Murphy (Galway, Ireland)
| |
Living with a rare disease: ELF Patient Ambassador Programme M. Fletcher (Warwick, United Kingdom)
| |
Discussion
| |
Pharma view on public private partnerships G. Recchia (Verona, Italy)
| |
Discussion
| |
Leaders report back to plenary P.J. Barnes (London, United Kingdom), S. Holgate (Southampton, United Kingdom), K.F. Rabe (Großhansdorf, Germany), T. Welte (Hanover, Germany), J-P. Sculier (Brussels, Belgium), J. Vestbo (Odense, Denmark), B. Flood (Wexford, Ireland)
| |